The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
FRUZAQLA (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
FRUZAQLA
Date registered
Evaluation commenced
Decision date
Approval time
165 (255 working days)
Active ingredients
fruquintinib
Registration type
NCE/NBE
Indication
FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and an anti-EGFR agent if appropriate.